Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
Jurewicz
W A
WA
D001379:Azathioprine / Q000627:therapeutic use; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008775:Methylprednisolone / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
D007166:Immunosuppressive Agents; D007328:Insulin; D014280:Triglycerides; D016572:Cyclosporine; D002784:Cholesterol; D003404:Creatinine; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus; D008775:Methylprednisolone